Invention Grant
- Patent Title: Synthetic plasmid DNA vaccine expressing a codon-optimized SARS-COV-2 spike protein
-
Application No.: US17203116Application Date: 2021-03-16
-
Publication No.: US11607449B2Publication Date: 2023-03-21
- Inventor: Anwar M. Hashem , Mohamed A. Alfaleh , Turki S. Abujamel , Sawsan S. Alamri , Abdullah Algaissi , Khalid A. Alluhaybi
- Applicant: KING ABDULAZIZ UNIVERISTY
- Applicant Address: SA Jeddah
- Assignee: KING ABDULAZIZ UNIVERISTY
- Current Assignee: KING ABDULAZIZ UNIVERISTY
- Current Assignee Address: SA Jeddah
- Agency: WCF IP
- Main IPC: A61K39/215
- IPC: A61K39/215 ; C07K14/165 ; C12N15/62 ; C12N15/85 ; C07K14/005 ; A61K39/00

Abstract:
A synthetic DNA vaccine against SARS-CoV-2 infection comprises a codon-optimized coding sequence for optimal mammalian expression of a pSARS2 spike glycoprotein (pSARS2-S). The signal peptide may be replaced with the signal peptide from the human IgG2 heavy chain. Systemic S1-specific IgG antibodies and neutralizing antibodies (nAbs) were significantly induced in mice at 2 weeks-post three injections with 100 μg of the pSARS2-S vaccine via intramuscular (IM) needle injection. IM immunization induced Th1-skewed and long-lasting IgG response in BALB/c mice. Immunogenicity and induction of nAbs were enhanced with a needle-free delivery system, wherein two doses were sufficient to elicit significant levels of systemic S1-specific IgG antibodies and nAbs via IM or intradermal immunization.
Public/Granted literature
Information query